Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors

Journal of the National Cancer Institute

Volumn 96, Issue 21, 2004, Pages 1611-1619

  Matsumoto, Koji ^a   Leggatt, Graham R ^a   Zhong, Jie ^a   Liu, Xiaosong ^a   de Kluyver, Rachel L ^a   Peters, Tania ^a   Fernando, Germain J P ^a   Liem, Amy ^b   Lambert, Paul F ^b   Frazer, Ian H ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KERATIN; PROTEIN E6; PROTEIN E7; TUMOR ANTIGEN; CYTOKERATIN 14; CYTOKINE; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; KRT1 14 PROTEIN, MOUSE; KRT1-14 PROTEIN, MOUSE; KRT14 PROTEIN, HUMAN; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; REPRESSOR PROTEIN;

ACTIVE IMMUNIZATION; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CANCER GRAFT; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; EPITHELIUM TUMOR; FLOW CYTOMETRY; GRAFT REJECTION; KERATINOCYTE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE TRANSFER; MEMORY CELL; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROMOTER REGION; SKIN; T LYMPHOCYTE; TISSUE INJURY; TRANSGENIC MOUSE; WART VIRUS; ANIMAL; CARCINOMA; CD8+ T LYMPHOCYTE; GENE EXPRESSION REGULATION; IMMUNOLOGY; SECRETION; SKIN TRANSPLANTATION; SKIN TUMOR;

ADJUVANTS, IMMUNOLOGIC; ADOPTIVE TRANSFER; ANIMALS; ANTIGEN PRESENTATION; CARCINOMA; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GRAFT REJECTION; IMMUNIZATION, PASSIVE; IMMUNOTHERAPY, ACTIVE; INTERFERON TYPE II; KERATIN-14; KERATINOCYTES; KERATINS; MICE; MICE, TRANSGENIC; ONCOGENE PROTEINS, VIRAL; REPRESSOR PROTEINS; SKIN NEOPLASMS; SKIN TRANSPLANTATION;

EID: 7944235613     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh301     Document Type: Article

References (45)

1. Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001;50:3-15.
2. Dupont B. Introduction: current concepts in immunity to human cancer and therapeutic antitumor vaccines. Immunol Rev 2002;188:5-8.
3. Kalos M. Tumor antigen-specific T cells and cancer immunotherapy: current issues and future prospects. Vaccine 2003;21:781-6.
4. Garcia-Lora A, Martinez M, Algarra I, Gaforio JJ, Garrido F. MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components. Int J Cancer 2003;106:521-7.
5. Ohshima K, Hamasaki M, Makimoto Y, Yoneda S, Fujii A, Takamatsu Y, et al. Differential chemokine, chemokine receptor, cytokine and cytokine receptor expression in pulmonary adenocarcinoma: diffuse down-regulation is associated with immune evasion and brain metastasis. Int J Oncol 2003;23:965-73.
6. Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells-a mechanism of immune evasion? Nat Med 1996;2:1361-6.
7. Pardoll D. Does the immune system see tumors as foreign or self? Annu Rev Immunol 2003;21:807-39.
8. Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 2004;4:46-55.
9. Frazer IH, De Kluyver R, Leggatt GR, Guo HY, Dunn L, White O, et al. Tolerance or immunity to a tumor antigen expressed in somatic cells can be determined by systemic proinflammatory signals at the time of first antigen exposure. J Immunol 2001;167:6180-7.
10. Dunn LA, Evander M, Tindle RW, Bulloch AL, De Kluyver RL, Fernando GJ, et al. Presentation of the HPV16E7 protein by skin grafts is insufficient to allow graft rejection in an E7-primed animal. Virology 1997;235:94-103.
11. Frazer IH, Leippe DM, Dunn LA, Liem A, Tindle RW, Fernando GJ, et al. Immunological responses in human papillomavirus 16 E6/E7-transgenic mice to E7 protein correlate with the presence of skin disease. Cancer Res 1995;55:2635-9.
12. Riley RR, Duensing S, Brake T, Munger K, Lambert PF, Arbeit JM. Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis. Cancer Res 2003;63:4862-71.
13. Wang X, Zinkel S, Polonsky K, Fuchs E. Transgenic studies with a keratin promoter-driven growth hormone transgene: prospects for gene therapy. Proc Natl Acad Sci U S A 1997;94:219-26.
14. Zhong J, Matsumoto K, De Kluyver R, Fernando GJ, Leggatt GR, Frazer IH. Human growth hormone (hGH) presented by K14hGH-transgenic skin grafts induces a strong immune response but no graft rejection. Immunol Cell Biol. In press 2004.
15. Fernando GJ, Murray B, Zhou J, Frazer IH. Expression, purification and immunological characterization of the transforming protein E7, from cervical cancer-associated human papillomavirus type 16. Clin Exp Immunol 1999;115:397-403.
16. Fernando GJ, Khammanivong V, Leggatt GR, Liu WJ, Frazer IH. The number of long-lasting functional memory CD8+ T cells generated depends on the nature of the initial non-specific stimulation. Eur J Immunol 2002;32:1541-9.
17. Azukizawa H, Kosaka H, Sano S, Heath WR, Takahashi I, Gao XH, et al. Induction of T-cell-mediated skin disease specific for antigen transgenically expressed in keratinocytes. Eur J Immunol 2003;33:1879-88.
18. Stewart TJ, Smyth MJ, Fernando GJ, Frazer IH, Leggatt GR. Inhibition of early tumor growth requires J alpha 18-positive (natural killer T) cells. Cancer Res 2003;63:3058-60.
19. Leggatt GR, Dunn LA, De Kluyver R, Stewart T, Frazer IH. Interferon-gamma enhances cytotoxic T lymphocyte recognition of endogenous peptide in keratinocytes without lowering the requirement for surface peptide. Immunol Cell Biol 2002;80:415-24.
20. Stefanski HE, Mayerova D, Jameson SC, Hogquist KA. A low affinity TCR ligand restores positive selection of CD8+ T cells in vivo. J Immunol 2001;166:6602-7.
21. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, De Jongh BM, Wouter Drijfhout J, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993;23:2242-9.
22. Jochmus-Kudielka I, Schneider A, Braun R, Kimmig R, Koldovsky U, Schneweis KE, et al. Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer. J Natl Cancer Inst 1989;81:1698-704.
23. Belz GT, Carbone FR, Heath WR. Cross-presentation of antigens by dendritic cells. Crit Rev Immunol 2002;22:439-48.
24. Ochsenbein AF, Sierro S, Odermatt B, Pericin M, Karrer U, Hermans J, et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 2001;411:1058-64.
25. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-4.
26. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 2002;99:16168-73.
27. Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, De Jong LA, Vyth-Dreese FA, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 2003;198:569-80.
28. Ferenczy A, Coutlee F, Franco E, Hankins C. Human papillomavirus and HIV coinfection and the risk of neoplasias of the lower genital tract: a review of recent developments. CMAJ 2003;169:431-4.
29. Sillman FH, Sentovich S, Shaffer D. Ano-genital neoplasia in renal transplant patients. Ann Transplant 1997;2:59-66.
30. Hopfl R, Heim K, Christensen N, Zumbach K, Wieland U, Volgger B, et al. Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7. Lancet 2000;356:1985-6.
31. Meschede W, Zumbach K, Braspenning J, Scheffner M, Benitez-Bribiesca L, Luande J, et al. Antibodies against early proteins of human papillomaviruses as diagnostic markers for invasive cervical cancer. J Clin Microbiol 1998;36:475-80.
32. Cohen PA, Peng L, Kjaergaard J, Plautz GE, Finke JH, Koski GK, et al. T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance. Crit Rev Immunol 2001;21:215-48.
33. Melief CJ, Van Der Burg SH, Toes RE, Ossendorp F, Offringa R. Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Immunol Rev 2002;188:177-82.
34. Klunker S, Trautmann A, Akdis M, Verhagen J, Schmid-Grendelmeier P, Blaser K, et al. A second step of chemotaxis after transendothelial migration: keratinocytes undergoing apoptosis release IFN-gamma-inducible protein 10, monokine induced by IFN-gamma, and IFN-gamma-inducible alpha-chemoattractant for T cell chemotaxis toward epidermis in atopic dermatitis. J Immunol 2003;171:1078-84.
35. Jung S, Unutmaz D, Wong P, Sano GI, los Santos K, Sparwasser T, et al. In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. Immunity 2002;17:211-20.
36. Carbone FR, Kurts C, Bennett SR, Miller JF, Heath WR. Cross-presentation: a general mechanism for CTL immunity and tolerance. Immunol Today 1998;19:368-73.
37. Savinov AY, Wong FS, Stonebraker AC, Chervonsky AV. Presentation of antigen by endothelial cells and chemoattraction are required for homing of insulin-specific CD8+ T cells. J Exp Med 2003;197:643-56.
38. Nowak AK, Lake RA, Marzo AL, Scott B, Heath WR, Collins EJ, et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 2003;170:4905-13.
39. Zhang M, Vacchio MS, Vistica BP, Lesage S, Egwuagu CE, Yu CR, et al. T cell tolerance to a neo-self antigen expressed by thymic epithelial cells: the soluble form is more effective than the membrane-bound form. J Immunol 2003;170:3954-62.
40. Yeung VP, Gieni RS, Umetsu DT, DeKruyff RH. Heat-killed Listeria monocytogenes as an adjuvant converts established marine Th2-dominated immune responses into Th1-dominated responses. J Immunol 1998;161:4146-52.
41. Poston RM, Kurlander RJ. Cytokine expression in vivo during murine listeriosis. Infection with live, virulent bacteria is required for monokine and lymphokine messenger RNA accumulation in the spleen. J Immunol 1992;149:3040-4.
42. Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, Altman JD, et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 1998;188:2205-13.
43. Nazaruk RA, Rochford R, Hobbs MV, Cannon MJ. Functional diversity of the CD8(+) T-cell response to Epstein-Barr virus (EBV): implications for the pathogenesis of EBV-associated lymphoproliferative disorders. Blood 1998;91:3875-83.
44. Kurts C, Sutherland RM, Davey G, Li M, Lew AM, Blanas E, et al. CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose. Proc Natl Acad Sci U S A 1999;96:12703-7.
45. Toes RE, Ossendorp F, Offringa R, Melief CJ. CD4 T cells and their role in antitumor immune responses. J Exp Med 1999;189:753-6.